Evidence map›Paper›PMID 37338403›Full record

ArticleJournal of clinical microbiology2023

A Selective Culture Medium for Screening Cefiderocol Resistance in

Ahmad Ibrahim, Maxime Bouvier, Mustafa Sadek, Jean-Winoc Decousser, Laurent Poirel, Patrice Nordmann

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical microbiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Ahmad IbrahimClinical Microbiology Unit, Pasteur Institute of Lille, Lille, France.ORCID 0000-0001-5358-1089
Maxime BouvierMedical and Molecular Microbiology, University of Fribourg, Fribourg, Switzerland.
Mustafa SadekMedical and Molecular Microbiology, University of Fribourg, Fribourg, Switzerland.ORCID 0000-0003-3983-3862
Jean-Winoc DecousserEquipe Opérationnelle d'Hygiène, Département Prévention, Diagnostic, Traitement des Infections, Hôpitaux Universitaires Henri-Mondor AP-HP, Créteil, France.ORCID 0000-0001-7105-6202
Laurent PoirelEuropean Institute for Emerging Antibiotic Resistance, Pasteur Institute, Lille, France.ORCID 0000-0001-5160-5286
Patrice NordmannEuropean Institute for Emerging Antibiotic Resistance, Pasteur Institute, Lille, France.ORCID 0000-0002-1343-1622

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cefiderocol (FDC) is a siderophore cephalosporin with a broad spectrum of activity against many multidrug-resistant Gram-negative bacteria. Acquired resistance to FDC has been already reported among Gram-negative isolates, thus highlighting the need for rapid and accurate identification of such resistant pathogens, in order to control their spread. Therefore, the SuperFDC medium was developed to screen FDC-resistant

Indexed as

Acinetobacter baumanniiAnti-Bacterial AgentsCefiderocolCephalosporinsDrug Resistance, Multiple, BacterialGram-Negative BacteriaHumansMicrobial Sensitivity TestsPseudomonas aeruginosaAnti-Bacterial AgentsCefiderocolCephalosporinscefiderocolculture mediummultidrug resistanceselective culture medium

Identifiers

PMID37338403
PMCPMC10358180

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.